Tags

Type your tag names separated by a space and hit enter

Reversible monoamine oxidase-A inhibitors in panic disorder.
Clin Neuropharmacol. 1993; 16 Suppl 2:S77-82.CN

Abstract

Monoamine oxidase (MAO) inhibitors are known to be effective in panic disorder, but a high incidence of adverse reactions have limited their use. The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated. This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia. Both treatments achieved a significant and comparable reduction in the number of panic attacks, and were equally effective in all the parameters measured. Side effects were typical of the drug class. Further trials are required to evaluate this promising new treatment.

Authors+Show Affiliations

University of Ottawa at Royal Ottawa Hospital, Ontario, Canada.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8313401

Citation

Bakish, D, et al. "Reversible Monoamine oxidase-A Inhibitors in Panic Disorder." Clinical Neuropharmacology, vol. 16 Suppl 2, 1993, pp. S77-82.
Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol. 1993;16 Suppl 2:S77-82.
Bakish, D., Saxena, B. M., Bowen, R., & D'Souza, J. (1993). Reversible monoamine oxidase-A inhibitors in panic disorder. Clinical Neuropharmacology, 16 Suppl 2, S77-82.
Bakish D, et al. Reversible Monoamine oxidase-A Inhibitors in Panic Disorder. Clin Neuropharmacol. 1993;16 Suppl 2:S77-82. PubMed PMID: 8313401.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reversible monoamine oxidase-A inhibitors in panic disorder. AU - Bakish,D, AU - Saxena,B M, AU - Bowen,R, AU - D'Souza,J, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - S77 EP - 82 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 16 Suppl 2 N2 - Monoamine oxidase (MAO) inhibitors are known to be effective in panic disorder, but a high incidence of adverse reactions have limited their use. The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated. This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia. Both treatments achieved a significant and comparable reduction in the number of panic attacks, and were equally effective in all the parameters measured. Side effects were typical of the drug class. Further trials are required to evaluate this promising new treatment. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/8313401/Reversible_monoamine_oxidase_A_inhibitors_in_panic_disorder_ L2 - https://medlineplus.gov/panicdisorder.html DB - PRIME DP - Unbound Medicine ER -